Phase
Condition
Vaginal Cancer
Pelvic Cancer
Vomiting
Treatment
Ondansetron
Neurokinin-1 Receptor Antagonist (NK1-RA)
Olanzapine
Clinical Study ID
Ages 18-89 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Diagnosis of gynecologic malignancy
No chemotherapy in the last 12 months
Scheduled to receive Carboplatin (AUC>=4) and Paclitaxel every three weeks
ECOG performance status 0 or 1
English speaking
Willing and able to provide informed consent
Laboratory values within protocol-defined parameters
No vomiting in the 24 hours prior to initiating chemotherapy
If childbearing potential exists, negative pregnancy test within 7 days prior toregistration
Exclusion
Exclusion Criteria:
Significant cognitive compromise
History of CNS disease (e.g. brain metastases, seizure disorder, dementia)
Current or recent (within 30 days) treatment with another antipsychotic agent (antidepressant medications are OK)
Concurrent radiotherapy treatment
Known hypersensitivity to olanzapine
Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardialinfarction within the last six months
History of diabetes mellitus on medication (insulin or oral glycemic agent)
Alcohol abuse / chronic alcoholism
History of closed angle glaucoma
Current enrollment in other clinical trials
Study Design
Connect with a study center
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan 48109
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.